# A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer

Joanie del Bano, Rémy Florès-Florès, Emmanuelle Josselin, Armelle Goubard, Laëtitia Ganier, Remy Castellano, Patrick Chames, Daniel Baty, Brigitte Kerfelec

► To cite this version:

Joanie del Bano, Rémy Florès-Florès, Emmanuelle Josselin, Armelle Goubard, Laëtitia Ganier, et al. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. Frontiers in Immunology, 2019, 10, pp.1593. 10.3389/fimmu.2019.01593. hal-02520930

HAL Id: hal-02520930

https://hal.science/hal-02520930

Submitted on 31 Mar 2020

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer

Joanie Del Bano¹, Rémy Florès-Florès², Emmanuelle Josselin¹, Armelle Goubard¹, Laetitia Ganier¹, Rémy Castellano¹, Patrick Chames¹, Daniel Baty¹ and Brigitte Kerfelec¹*

¹ Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmette, CRCM, Marseille, France, ² Aix Marseille Univ, CNRS, Institut de Biologie du Développement de Marseille, UMR7288, Marseille, France

Triple negative breast cancers (TNBC) remain a major medical challenge due to poor prognosis and limited treatment options. Mesothelin is a glycosyl-phosphatidyl inositol-linked membrane protein with restricted normal expression and high level expression in a large proportion of TNBC, thus qualifying as an attractive target. Its overexpression in breast tumors has been recently correlated with a decreased disease-free survival and an increase of distant metastases. The objective of the study was to investigate the relevance of a bispecific antibody-based immunotherapy approach through mesothelin targeting and CD16 engagement using a Fab-like bispecific format (MesobsFab). Using two TNBC cell lines with different level of surface mesothelin and epithelial/mesenchymal phenotypes, we showed that, *in vitro*, MesobsFab promotes the recruitment and penetration of NK cells into tumor spheroids, induces potent dose-dependent cell-mediated cytotoxicity of mesothelin-positive tumor cells, cytokine secretion, and decreases cell invasiveness. MesobsFab was able to induce cytotoxicity in resting human peripheral blood mononuclear cells (PBMC), mainly through its NK cells-mediated antibody dependent cell cytotoxicity (ADCC) activity. *In vivo*, the anti-tumor effect of MesobsFab depends upon a threshold of MSLN density on target cells. Collectively our data support mesothelin as a relevant therapeutic target for the subset of TNBC that overexpresses mesothelin characterized by a low overall and disease-free survival as well as the potential of MesobsFab as antibody-based immunotherapeutics.

**Keywords:** bispecific antibody (bsAb), natural killer cells, immunotherapy, triple negative breast cancer (TNBC), mesothelin (MSLN), multicellular tumor spheroid model (MCTS)

## INTRODUCTION

Over the past 15 years, the enrichment of the diagnosis and therapeutic arsenal against breast cancers has undoubtedly contributed to improving their prognosis. However, despite these advances, recurrences still occur and metastatic breast cancer remains in most cases an incurable disease. Moreover, therapeutic failures are still frequent either because of intrinsic or acquired resistance to treatment, especially in the case of so-called triple-negative breast cancers (TNBC). Indeed TNBC which represent 10–20% of invasive breast cancers account for the majority of deaths in breast cancer patients due to a higher recurrence rate and a worse overall survival rate than other subtypes of breast cancer (1). Apart from their aggressiveness and their ability to rapidly

**OPEN ACCESS**

**Edited by:**
Nurit Hollander,
Tel Aviv University, Israel

**Reviewed by:**
Roland E. Kontermann,
University of Stuttgart, Germany
Pappanaicken R. Kumaresan,
University of Texas MD Anderson
Cancer Center, United States

*Correspondence:
Brigitte Kerfelec
brigitte.kerfelec@inserm.fr

**Specialty section:**
This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Immunology

**Received:** 13 December 2018

**Accepted:** 26 June 2019

**Published:** 10 July 2019

**Citation:**
Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, Chames P, Baty D and Kerfelec B (2019) A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. *Front. Immunol.* 10:1593.
doi: 10.3389/fimmu.2019.01593
metastasize, these cancers are characterized by a strong heterogeneity and the lack of markers such as HER2, estrogen and progesterone receptors, and a variable response to treatment. Treatment options still remain limited with chemotherapy being the standard of care treatment. Therefore, the development of new strategies and/or new therapeutic molecules for these dark prognosis cancers is a major clinical challenge.

Mesothelin (MSLN), a 40 kDa glycosyl-phosphatidyl inositol-
linked (GPI) membrane glycoprotein, has been attracting
growing interest in the field of cancer therapy. In healthy
tissues, MSLN is only expressed on mesothelial cells lining the
peritoneum, pericardium, and pleura (2). The most common
form of MSLN is membrane-bound but a soluble form devoid
of GPI anchor has also been described (3, 4). Apart from its
presumed role in cell-cell adhesion, its biological function is still
not fully understood and its knockout in mice has no detectable
phenotype (5). MSLN is overexpressed in several human cancers,
notably those characterized by aggressive phenotypes and poor
prognosis such as mesotheliomas, pancreatobiliary, ovarian,
and lung carcinoma (6). High amount of soluble MSLN has
been also reported in the serum of patients with ovarian
cancer. In a tumor context, MSLN plays an important role in
survival, proliferation, and migration/invasion of cancer cells
as well as in drug resistance, potentially through the Wnt/NF-
κB/PI3K/Akt signaling pathways (7) and/or by facilitating the
anchorage-independent growth (8). An association between
MSLN expression, tumor invasion and matrix metalloproteinases
activation has been demonstrated *in vitro*, *in vivo*, and
in patients with malignant pleural mesothelioma (9). Its
strong interaction with MUC16 (CA125), a large membrane-
spanning glycoprotein, contributes to peritoneal spread in
ovarian cancer by promoting heterotypic cell adhesion (10)
and increases the motility and invasiveness of pancreatic
cancer cells (11). In mouse models of pancreatic cancer,
MSLN overexpression promotes metastasis and proliferation
of tumor cells. The causes of MSLN overexpression in cancer
are not clear but could be related to the hypomethylation of
MSLN gene (12) or the deregulation of the Wnt signaling
pathways (13).

Confirming the interest of MSLN as therapeutic target,
a growing number of clinical trials are currently ongoing
at different stages for evaluating diverse MSLN targeted
strategies such as vaccines, antibody drug conjugate, monoclonal
antibodies (Morab-009), Meso CART-cells (6, 14, 15), or
combinations (16). Overexpression of MSLN was recently
demonstrated in TNBC. Depending on the scoring system, the
percentage of MSLN positive TNBC among TNBC varies from 36
to 63% (17, 18) and although controversial (19, 20), a correlation
with lymph nodes infiltration and poor overall survival has been
described in MSLN-positive TNBC (18).

In this study, we exploited a previously described single
domain-based bispecific antibody Fab-like format (21, 22) to
generate a bispecific antibody targeting MSLN and FcγRIII
(CD16), one of the strongest activating receptor notably
expressed by NK cells. Its antitumor efficacy was evaluated
*in vitro* on 2D (monolayer) and 3D (spheroid) TNBC culture
models and *in vivo* in two TNBC xenograft mice models.

RESULTS

Design and Characterization of Anti-MSLN
x CD16 Bispecific Antibody

Based on our proprietary Fab-like bispecific format (bsFab)
and previously characterized anti-MSLN [clone A1, (23)]
and anti-CD16 [clone C21, (24)] nanobodies, we designed
a bsFab (MesobsFab) targeting mesothelin positive tumor
cells and CD16 positive immune cells (Figure S1A). Binding
properties of MesobsFab were investigated by flow cytometry
on HCC1806 cell line and on human CD16-transfected Jurkat
cells (Figure S1). Consistent with our previous data (21, 22),
MesobsFab exhibited a high apparent affinity for CD16 with
a low K<sub>Dapp</sub> value (1.8 ± 0.8 nM), compared to that of
conventional human IgG Fc fragment (>100 nM) (Table S1).
The K<sub>Dapp</sub> values on HCC1806 cells (4.7 ± 0.9 nM) were in
good agreement with previous data obtained with the anti-
MSLN sdAb A1 on HELA cells (23), indicating that the specific
binding activity of this sdAb was retained in the bispecific
format. MesobsFab specificity was also confirmed by competition
assays (Figure S1).

MesobsFab Decreases the Invasive
Properties of TNBC Cell Lines *in vitro*

MSLN overexpression has been reported to be associated with
a strongly invasive and aggressive tumor phenotype in TNBC.
Based on the hypothesis that the binding of MesoFab to
MSLN might interfere with this property, we investigated the
potential effects of MesobsFab on the *in vitro* migration/invasion
properties of MDA MB 231 and HCC1807 cells. MesobsFab
displayed a reproducible tendency to slightly decrease the
migration of HCC1806 and MDA MB 231 cells without reaching
significance (Figure 1A). By contrast, a significant decrease of
both MDA MB 231 and HCC1806 invasiveness was observed in
the presence of MesobsFab (Figure 1B).

Formation of Homotypic Multicellular
Tumor Spheroids Derived From TNBC Cells

Homotypic spheroids were generated from the two TNBC cell
lines using the static liquid overlay method (3, 25). Growth
of spheroids and changes in morphology were monitored
by phase contrast light microscopy. TNBC cells formed cell
clusters within 24 h after seeding and reached a characteristic
3D organization after 2-4 days as shown by the formation of
more or less compact and round-shaped spheroids and the
disappearance of cells in suspension in the growth medium.
The mean radius of 4-days spheroids (CV > 10%) was similar
for MDA MB 231 and HCC1806 spheroids (222.9 ± 16.8 vs.
224.1 ± 17.9 µm, respectively). HCC1806 spheroids displayed
a rather rounded and compact morphology while MDA MB
231 spheroids were less regular and less compact likely due
to weaker cell-cell contacts (Figure 2A). As described in the
literature, the spheroid periphery consisted of viable cells
while necrotic cells were located in the core as evidenced by
Hoechst 3342 and Propidium Iodide (PI) staining (Figure S2A).
Evolution of cell death during spheroid growth was monitored
by PI staining at different time points, revealing a discrete
<figure><img src="image_2.png" /></figure>

**FIGURE 1** | MesobsFab binding to mesothelin reduces HCC1806 invasiveness. Effect of MesobsFab or control bsFab (50 nM) on the migration and invasion of MDA MB 231 and HCC1806 cells. (A) CFSE-stained tumor cells were allowed to migrate toward culture medium supplemented with 5% FBS for 6 or 24 h at 37°C. The fluorescence signals measured in the Fluoroblok bottom chambers correspond to migrating cells. A control of low migration was performed by omitting the FBS in the culture medium. (B) CFSE-stained MDA MB 231 and HCC1806 cells were seeded onto a matrigel coated fluoroblok inserts and allowed to migrate in response to serum gradient. 100% inhibition corresponds to the absence of CFSE-stained tumor cells in the bottom chamber. In all panels, data represent the mean ± SEM from 3 independent experiments. Statistical significance was determined by two-tailed Student's t-test: \*P < 0.05, \*\*P < 0.001, MesobsFab vs. control bsFab.

area of necrosis already at day 4 which increased over time (Figures S2B,C). The necrosis process was more pronounced in the HCC1806-spheroids than in the MDA MB 231-spheroids and was accompanied by a visible cellular migration phenomenon. Epithelial/mesenchymal phenotypes of TNBC spheroids were investigated by immunochemistry on 7-day spheroids through the expression of epithelial (E-cadherin) or mesenchymal (Vimentin) markers. MDA MB 231 spheroids presented a high vimentin staining (Figure 2B) and a low E-cadherin expression (Figure 2C) characterizing a mesenchymal-like phenotype while HCC1806 spheroids displayed a strong E-cadherin staining and a lack of vimentin expression suggesting an epithelial phenotype.

The specific antibody binding capacity (SABC) reflecting the antigen density of MDA MB 231 cells was significantly lower than that of HCC1806 but still significantly higher than that of MSLN-negative cells BT-474 (Figure 2D). A slight but significant (*p* < 0.05) increase of MSLN binding capacity was observed on HCC1806 spheroids compared to 2D monolayers.

Analysis of migration/invasion patterns demonstrated that MDA MB 231 cells disseminated outside the spheroids mainly as cell clusters and displayed heterogeneous rounded and elongated morphologies (Figure 2E). In the presence of matrigel, MDA MB 231 spheroids formed invasive spike-like protrusions (Figure 2F), typical of mesenchymal-like phenotype. By contrast, the migration/invasion pattern of HCC1806

cells in 3D resembled amoeboid migration and bud-like invasion phenotype.

## NK Cells Recruitment and Infiltration Into TNBC Spheroid

Human resting NK cell recruitment and infiltration mediated by MesobsFab were investigated on HCC1806 spheroids by light-sheet fluorescence microscopy. CFSE-stained HCC1806 spheroids were co-cultured with PKH-26 stained NK cells with or without MesobsFab or control bsFab. After spheroid reconstruction, qualitative and quantitative analysis were performed as depicted in Figure 3A for MesobsFab and control bsFab or IgG (Movie S1) using 3D analysis method on ImageJ software. NK cells infiltration was evaluated on 3D reconstructed images by measuring the distance of each NK cell from the spheroid surface and not from the spheroid center to overcome spheroid sphericity problems. NK cells (red dots) spontaneously infiltrated HCC1806 spheroids and most NK cells accumulated at the periphery of the tumor spheroids (Figure 3B). A significantly higher recruitment of NK cells was observed in the presence of MesobsFab, compared with control conditions without antibody (Figure 3C). Surprisingly, the control antibodies (bsFab or human IgG) also induced a significant NK cells recruitment. The control bsFab behaved similarly to MesobsFab while IgG was less effective. Using a cumulative distribution curve (Figure 3D)
<figure><img src="image_3.png" /><figcaption>**FIGURE 2** | Characterization and phenotypic properties of TNBC spheroids. (A) Representative bright field images of MDA MB 231 and HCC1806 spheroids. (B,C) Epithelial/mesenchymal phenotypes of MDA MB 231 and HCC1806 spheroids. Representative images of E-cadherin (B) and vimentin (C) staining of histological sections of 7 day- spheroids. Scale bar, 500 µm. (D) Specific MSLN binding capacities of 2D and 3D MDA MB 231, HCC1806, and BT474 cell cultures. Values with errors bars represent mean ± SEM (n = 3). Data were analyzed by two-tailed Student's t-test. \*P < 0.05, HCC1806 2D vs. 3D models; \*\*P < 0.001, 2D MDA MB 231 vs. BT474. (E,F) Migration/invasion patterns of MDA MB 231 and HCC1806 spheroids. Representative images of migration (E) and invasion (F) pattern of 4 days spheroids were transferred on 1% gelatin or embedded in 50% matrigel, respectively, and cultured for 2 days at 37°C before imaging. Images were acquired with an EVOS FL Auto microscope. Scale bar, 500 µm.</figcaption></figure>

we showed that the probability to find NK cells deeper into the spheroid was higher in the presence of MesobsFab or control bsFab, and to lesser extent in the presence of control IgG compared to the absence of antibody.

## In vitro MesobsFab Mediates ADCC Against 2D and 3D TNBC Cell Culture Models

The capacity of MesobsFab to mediate antibody dependent cell cytotoxicity (ADCC) was evaluated on both tumor cell monolayers and spheroids. In both cases, tumor cells were co-incubated with unstimulated human NK cells for 12 h and target cell viability was measured either by CellTiter-Glo viability assay for 2D cell culture or by flow cytometry for 3D culture

system. Before 3D experiments, the size homogeneity of all CFSE-stained spheroids was checked using ImageJ software. MesobsFab elicited NK cell cytotoxic in a dose-dependent manner at an effector:target (E:T) ratio of 10:1 on all culture models but differences were noticed (Figure 4A). In agreement with MSLN expression level, MesobsFab displayed a higher efficacy (maximal lysis) on HCC1806 than on MDA MB 231 monolayers (77% for HCC1806 vs. 35% for MDA MB 231) but this difference faded when cells were grown as spheroids (Lysis max: 46-49%). MesobsFab was as efficient against MDA MB 231 spheroids than against 2D monolayers, with a maximal specific lysis ranging from 35 to 46% but its potency was affected as evidenced by the large shift of the EC₅₀ values on spheroids (26 vs. 919 pM). On the other hand, both the efficacy and the potency of MesobsFab
<figure><img src="image_4.png" /><figcaption>**FIGURE 3** | Impact of MesobsFab on NK cells infiltration into TNBC spheroids. (A) Cross-sections illustrating the 3D distance analysis method using ImageJ software. Multi-views images of spheroid were fused at 488 nm for visualizing CFSE-labeled tumor cells (A.4) and 561 nm for PKH-26-labeled NK cells (A.1). A Laplacian of Gaussian filter was applied to spatially filter the NK cells (A.2), then the NK cells were detected by measuring local maxima (A.3). A 3D mask (A.5) was created based on CFSE-labeled tumor cells (A.4) and used for measuring the distance of each NK cells from the spheroid surface (A.6) by computing the mask distance transform (A.5). (B) Representative images of infiltrated NK cells (red dots) into spheroid treated by MesobsFab, control bsFab, or without antibody. (C) Total number of NK cell detected into HCC1806 spheroid after 2 days of co-culture (E:T ratio 2.5:1) in the presence or absence of bsFab (50 nM). (D) Cumulative distribution curve representing the probability of NK cell infiltration based on the distance penetration. All spheroids size were homogeneous (CV < 6%) and had a radius size of 188.4 ± 10, 7 µm (n = 5–6/group). Data points represent the mean ± SEM and were analyzed by two-tailed Student's t-test. \*\*P < 0.01 MesobsFab vs. no Ab.</figcaption></figure>

decreased on HCC1806 spheroids compared to 2D monolayers, despite a higher MSLN binding capacity. Of note, a slightly higher spontaneous NK cells-mediated lysis on spheroids was observed, reaching about 30% (vs. 10–15% on monolayers). As previously described, engagement of CD16 in MesobsFab-driven ADCC was confirmed by measuring extracellular granzyme B (Figure S3A). The specificity of MesobsFab-mediated ADCC was demonstrated using either a control bsFab at the highest

concentration 50 nM (Figure 4A) or MSLN-negative tumor cells (Figure S3B). Noticeable differences were observed between the 2 TNBC cell lines when the impact of E:T ratio was investigated (Figure 4B). Indeed, MesobsFab retained its cytotoxic activity at low E:T ratio on MDA MB 231 spheroids compared to control bsFab whereas its activity dropped rapidly with the E:T ratio on 2D cultures. By contrast, MesobsFab efficacy against HCC1806 was significantly higher than that of the
<figure><img src="image_5.png" /></figure>

**FIGURE 4** | MesobsFab mediates potent *in vitro* ADCC activity against TNBC cell lines. (A) ADCC assays were performed on 2D and 3D cell models using serial dilutions of MesobsFab, unstimulated NK cells as effector cells and MDA MB 231 or HCC1806 as target cells (E:T ratio 10:1). Control bsFab was tested at the highest concentration (50 nM). Target cell viability was determined by CellTiter-Glo viability assay for 2D ADCC or by flow cytometry after spheroid dissociation for 3D ADCC. (B) Impact of the E:T ratios on the maximal lysis of MDA MB 231 and HCC 1806 monolayers and spheroids mediated by 5 nM, (EC90) MesobsFab or control bsFab. Data shown are mean ± SEM from 3 independent experiments (3 donors). Statistical analysis was performed by two-tailed Student's t-test. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001.

control bsFab at E:T ratio of 10 and 2.5, regardless of the cell growth conditions. A slight increase of tumor lysis mediated by the control bsFab was observed at high E:T ratio on spheroids.

Finally, the activation status of NK cells harvested from the above 2D and 3D ADCC assays was evaluated by measuring the secretion of inflammatory cytokines, TNFα and INFγ. The tumor cell growth conditions had a strong influence on the level of IFNγ secretion with a substantially higher MesobsFab-mediated release of IFNγ during 3D ADCC (10 to 40-fold) compared to 2D ADCC at different E:T ratio (Figure 5A). This result was observed at all E:T ratio with MDA MB 231-derived spheroids. At E:T ratio of 10, the control bsFab did lead to a small but significant IFNγ secretion in the 3D but not in the 2D model compared to NK cell alone. However, this secretion remained significantly lower than that mediated by MesobsFab.

A significant release of TNFα was observed during MesobsFab-mediated ADCC against MDA MB 231 monolayers at all E:T ratio but only at high E:T ratio on MDA-MB 231-derived spheroids. By contrast, no increase of TNFα release was observed during MesobsFab-mediated ADCC against HCC1806, except at high E:T ratio against HCC1806 monolayers (Figure 5B).

## *In vivo* Antitumor Efficacy of MesobsFab Against TNBC Tumors

As illustrated in Figure 6A, we first confirmed that MesobsFab retained its ADCC activity using unstimulated peripheral blood mononuclear cells (PBMC) as effector cells (E:T ratio = 25). As expected, depletion of NK cells led to a significant drop in activity, confirming the predominant role of this cells in MesobsFab cytotoxic activity. Next, we investigated the *in vivo* antitumor efficacy of MesobsFab in MDA MB 231 and HCC1806 orthotopic xenograft models in PBMC-humanized NSG mice. Based on preliminary experiments on tumor cell growth with or without PBMC, the antibody treatment and PBMC transplant protocol were adapted for each model. Untreated (PBS) or (human IgG + PBMC) treated mice were used as controls. During the treatment, MesobsFab was administered every day during 12 days to compensate for its short half-life compared to every 3-days for human IgG. As shown in Figure 6B, a significant and sustained retardation of HCC1806 tumor growth was observed in MesobsFab treated mice compared to control mice (p < 0.001). For MDA MB 231 mice models, a modest but significant (p < 0.001) slowdown in tumor growth was induced after treatment (from day 41) by MesobsFab compared to untreated mice but not to IgG-treated mice (Figure 6C). Monitoring of animal survival and weight curves indicated
A MDA MB 231

<figure><img src="image_6.png" /></figure>

HCC1806

<figure><img src="image_7.png" /></figure>

B

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

**FIGURE 5** | MesobsFab mediates potent IFNγ secretion. IFNγ (A) and TNFα (B) were quantified by ELISA in the culture medium harvested from ADCC assays. Experiments, performed in technical triplicate, are representative of at least three independent donors. Data represent the mean ± SEM and were analyzed by two-tailed Student's t-test. MesobsFab vs. control bsFab: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001; MesobsFab 2D vs. MesobsFab 3D \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

no apparent off target toxicity of MesobsFab, despite repeated
injections but GvH effect started to appear in MBMC treated
mice at day 22 and 48 for HCC1806 and MDA MB 231.

DISCUSSION

Despite a significant overall decrease in breast cancer-related
mortality explained by major improvements in early detection
and therapeutic strategies, triple negative breast cancers which
are clinically defined by the absence of hormonal and HER2
receptors, remain a clinical challenge with limited therapeutic
options and the worse overall survival. Thanks to continuous
and major advance in immuno-oncology, new tracks of
targeted therapies are being explored (26). Among these tracks,
mesothelin has recently emerged as a “hot prospect” because
of its restricted expression on mesothelial cells in healthy
tissues and its over-expression in several aggressive cancers and
notably in 30-70% of TNBC (6, 16, 27). Moreover, although

controversial, the over-expression of MSLN in TNBC seems
associated with a poor prognosis (18, 19). These features led
to the development of different anti-MSLN therapeutic agents
(16, 28). Amatuximab (MORAb-009) is currently the only
unconjugated anti-MSLN monoclonal antibody examined in
clinical trials but its therapeutic efficacy as single agent is
disappointing (14), reinforcing the need to find new anti-MSLN
antibody-based therapies.

In this context, we evaluated a bispecific antibody retargeting
strategy aiming at engaging CD16 expressing effectors to tumor
site in TNBC using a versatile Fab-like bispecific antibody
format derived from llama single domain antibodies (21, 22).
Endowed with original features such as a unique, specific,
and high CD16 binding apparent affinity, this format has
been shown to overcome limitations of monoclonal antibodies
associated with low affinity for CD16 polymorphism sensitivity
(21, 22). The previously characterized anti-MSLN single domain
antibody A1 (23) was used to develop a Fab-like bispecific
antibody, MesobsFab, which targets MSLN on tumor cells
<figure><img src="image_10.png" /></figure>

**FIGURE 6** | MesobsFab antitumoral efficacy in vivo. (A) Left panel: frequency of CD56+CD16+ cells in PBMC before and after depletion of CD56 cells. The percentage of CD56+CD16+ double-positive cells in the PBMC population is indicated. Cells were labeled with CD56-APC, CD16-PE antibodies. Right panel: flow cytometry-based ADCC assays were performed on 2D cell models using 40 nM of bsFab, unstimulated PBMC (white bar), or CD56-depleted PBMC (gray bar) as effector cells and HCC1806 as target cells (E:T ratio 25:1). CFSE-labeled target cells mortality was determined by staining with TO-PRO3. Specific cell lysis was determined using the formula: $[TEA CFSE+ TO-PRO3+ - TE CFSE+ TO-PRO3+/100 - ET CFSE+ TO-142 PRO+]/100$ with TEA = Target + Effector + Antibody, TO-PRO3+ = Target + Effector. Data are presented as mean ± SEM of four independent experiments (4 healthy donors). P values were determined by one-tailed unpaired t-test: \*P < 0.05; MesobsFab/PBMC vs. MesobsFab/PBMC CD56<sup>-</sup>; \*\*P < 0.05; MesobsFab vs. control bsFab. HCC1806 tumors (B) and MDA MB 231 tumor (C) growth in NSG mice that received unstimulated human PBMC twice (arrows) and treated with MesobsFab (5 mg/kg) every day for 12 days, irrelevant human IgG (5 mg/kg) 3 times a week or vehicle (PBS), (n = 5-6 mice/group). Duration of treatment is represented by the black line. Tumor growth was followed using a Vernier caliper. Data are presented as mean tumor volume ± SEM. P value were determined by two-way ANOVA with Bonferroni post tests. HCC1806: \*\*\*P < 0.001 MesobsFab vs. Hu IgG (D19 and D22); \*\*\*P < 0.001 MesobsFab vs. Hu IgG (D22). MDA MB 231: \*P < 0.05 MesobsFab vs. PBS (D48), \*\*\*P < 0.001 MesobsFab vs. PBS (D51), \*\*\*P < 0.001 Hu IgG vs. PBS (D48 and D51).

and CD16 expressing effector cells such as NK cells. Two TNBC cell lines, MDA MB 231 and HCC1806, with different epithelial/mesenchymal phenotypes and MSLN expression level were chosen as TNBC models.

We demonstrated that binding of membrane-bound MSLN by MesobsFab significantly decreased the invasiveness of both TNBC cells but had no effect on cell migration. Disruption of MSLN/MUC16 interaction by MesobsFab cannot explain this result because MUC16 expression has not been documented in breast cancer (29). A potential explanation of this result could be an indirect effect of MesobsFab on the MSLN-driven secretion of matrix metalloproteases, notably MMP-7 and MMP-9 which have been described as promoting tumor invasion (9, 11, 30, 31). Although some of our preliminary data indicate that invading HCC1806 cells secrete high amount of MMP-9 and that this secretion is significantly reduced by MesobsFab

binding to MSLN, further investigation are required to delineate the impact of MesobsFab/MSLN interaction on MMPs secretion and invasive capacities in TNBC.

Compelling evidence has shown that spheroids, although lacking solid tumor complexity, recapitulate some of the morphological, histological, and physiological characteristics of solid tumors (32, 33). By mimicking the architecture of small avascularized tumor nodules, spheroids constitute attractive alternative models for testing the effectiveness of putative therapeutic molecules and for exploring some issues that cannot be addressed by conventional monolayer culture such as immune cell infiltration in tumors or the impact of the 3D organization of tumor cells on ADCC. In this study, multicellular tumor spheroids of TNBC were developed in parallel with conventional 2D cell monolayers. HCC1806- and MDA MB 231-derived spheroids displayed striking differences in terms
of morphological and immunohistochemical characteristics as well as migration/invasion patterns and MSLN expression, reflecting the heterogeneity of TNBC. Given the critical impact of immune infiltration in these tumors we took benefit of our 3D culture models to investigate the capacity of MesobsFab to mediate NK cells recruitment and infiltration. Although spheroids are more and more used to mimic the impact of the tumor microenvironment on NK cell function, they are scarcely used to investigate the process of recruitment, infiltration and immunosurveillance. Infiltrated NK cells were detected by lightsheet fluorescence microscopy which allows live imaging and non-invasive optical sectioning of fluorescently labeled 3D samples (34, 35), thus bypassing the disadvantage associated with spheroids fixation and sectioning in immunohistochemistry analysis. A 3D analysis method based on Bayesian multiview deconvolution (36) was developed to quantify and localize any NK cells infiltrated into spheroids. We show that MesobsFab enhanced NK cell recruitment and increased the number and the probability of NK cell penetration in deeper distances compared to NK cell/spheroids alone. Unexpectedly, the control bsFab recruited as much NK cells as MesobsFab and favored NK cell infiltration. Similar results, but to a lesser extent, were observed with control human IgG which displays a lower affinity for CD16 compared to that of MesobsFab. Importantly, none of these control antibodies bind tumor cells nor trigger cytotoxic activity on HCC1806 spheroids. These counterintuitive results suggest that the monovalent engagement of CD16 on NK cells might contribute to the recruitment and infiltration of NK cells. Yet beyond the scope of this study, further investigations are currently ongoing to explain these results and better understand the dynamic of NK cell recruitment within the tumor environment.

We next assessed the ability of MesobsFab to trigger NK cell cytotoxicity against TNBC cells *in vitro*. For sake of comparison, we chose to keep similar experimental set up for 2D and 3D ADCC assays, using the same starting number of tumor cells, E:T and incubation time. We showed that MesobsFab elicited efficient and potent ADCC using unstimulated human NK cells against the two TNBC cells cultured in both 2D or 3D conditions. MesobsFab induced granzyme/perforin-mediated cytotoxicity and cytokine secretion in response to target cell recognition and CD16 engagement. However, the 3D organization of tumor cells proved to have an influence on the tumor cells susceptibility to NK cell cytotoxicity, on MesobsFab efficacy (maximal lysis) and potency ($EC_{50}$) and on cytokine secretion in response to MesobsFab driven CD16 engagement. Thus, a higher non-specific lysis mediated by the control bsFab was observed on spheroids perhaps reflecting the recruitment and infiltration of NK observed in these conditions that might translate to increased natural cytotoxicity. The efficacy of MesobsFab was strongly dependent on the E:T ratio on both cell lines in 2D; this parameter appeared to have a lower impact in 3D, notably with MDA MB 231 cells. As well, a tremendous increase of $IFN\gamma$ secretion was observed when tumor cells were grown as spheroids reflecting a strong NK cell activation mainly dependent on tumor cell/immune cell cross-linking. One potential explanation could be that the spatial environment and

the high density of target cells in 3D format enhances NK cell activation by promoting MesobsFab mediated serial contacts between NK and tumor cells (37, 38) and/or the engagement of other activating receptors such as NKG2D or NKp46 which has been shown to trigger $IFN\gamma$ secretion (39). Yet, MDA MB 231 cells express several NKG2D ligands (40). This finding is of interest as the presence of $IFN\gamma$ in the tumor microenvironment promotes immune cells activation and tumor immunogenicity shaping (41). No increase in $TNF\alpha$ secretion was observed although Fauriat et al. (42) described an interrelationship between $IFN\gamma$ and $TNF\alpha$ secretion. Importantly, the low level of cytokine secretion by NK cells induced by MesobsFab in the absence of target cells *in vitro* suggests that MesobsFab should not trigger any systemic activation of NK cells *in vivo* and should not induce cytokine storm. Moreover, we previously showed that the presence of neutrophils, expressing CD16B, a non-signaling GPI-linked version of the receptor, did not disturb NK cell-mediated ADCC, at least *in vitro* on tumor cell monolayers (22).

Validation of the *in vivo* efficacy of new immunotherapies remains a real brainteaser as these approaches require a functional immune system. In this respect, syngeneic transplantable models are attractive models but many differences between human and mouse immune systems represent a major limitation that might account for the regular differences experienced between pre-clinical and clinical immune-based studies. An extra level of complexity resides in the fact that overexpression of mesothelin in immunocompetent mice has been shown to inhibit tumor formation (43). For mimicking a human tumor/immune system context, the *in vivo* efficacy of MesobsFab was thus evaluated in a model of PBMC humanized mice generated by human PBMC engraftment and orthotopic MDA MB 231 or HCC1806 xenografts in severe immunodeficient mice (NSG). Despite the scarcity of human NK cells due to their short life span in such model, a significant slowdown of HCC1806 tumor growth mediated by MesobsFab was observed. On the other hand, its impact on MDA MB 231 tumor growth did not reach significance relative to human IgG-treated mice. This result suggests that *in vivo* the anti-tumor efficacy of MesobsFab depends upon a threshold of MSLN density on target cells. This finding is at variance with those observed *in vitro* with tumor spheroids which suggested a low impact of MSLN expression level on MesobsFab efficacy. The efficacy of MesobsFab on MSLN-positive TNBC could be of particular interest as this subgroup was described to display a short interval to metastasis and high risk of developing brain metastasis (18). Further investigations on additional MSLN-positive TNBC cell lines will be necessary to confirm this result. Besides, although CD56 depletion of human PBMC confirmed the pivotal role of NK cells in the cytotoxic activity of MesobsFab, the potential role of other CD16-positive effector cells in the cytotoxic activity of MesobsFab could be an interesting issue to investigate as the importance of CD16 engagement has been recently reported for monocytes-mediated ADCC (44), neutrophil activation (45) or NK cell proliferation and memory-like cytotoxicity (46). As well, the use of more advanced models such as human IL-15 expressing NOG mice engrafted with human CD56+ cells derived from PBMC or human hematopoietic stem cells to
sustain and amplify NK cells should be the next step to ascertain
the *in vivo* efficacy of MesobsFab and investigate the long term
effect of MesobsFab. As well, due to the scheduling of the
treatment and the short *in vivo* half-life of MesobsFab (21), it can
be assumed that it is no longer present during the last 15 days
of the experiment. Strategies that significantly increase tumor
retention can be envisaged such as continuous infusion, a process
described for BiTEs (47) or the addition of an anti-human serum
albumin sdAb to confer a long serum half-life to the bsFab
format (48).

Collectively, our data support the potential of targeting
mesothelin in mesothelin-positive TNBC using MesobsFab as a
new targeted immunotherapy.

METHODS

Cells

BT-474 (ATCC HTB-20), HCC1806 (ATCC® CRL-2335™), SK-
BR-3 (ATCC® HTB-30™) and MDA-MB-231 (ATCC® HTB-
26™) were purchased from ATCC. Ovarian cancer cells line,
A1847 and human FcyRIIIA transfected Jurkat lymphoma T
cells (Jurkat-huFcγRIIIA cells) were a gift of Dr N. Scholler,
(SRI International, Ca USA) and Pr. Eric Vivier (Marseille,
France), respectively, and were not authenticated. NK cells
were isolated from human PBMCs as previously described
(21). NK cells purity and activation status were determined
by flow cytometry (MACSQuant® analyser (Miltenyi Biotec)
after staining with PE-conjugated anti-CD3, anti-CD56, anti-
CD16, anti-CD69, and anti-CD107 (Miltenyi Biotec). Mesothelin
binding capacity of tumor cell lines was quantified by DAKO
QIFIKIT (DAKO Cytomation), according to manufacturer's
protocol using anti-human mesothelin monoclonal antibody K1
(GTX23362, GeneTex) as primary antibody. MSLN quantity
was expressed as specific antibody-binding capacity units after
subtracting background from isotype control.

Multicellular Tumor Spheroid Formation

Multicellular tumor spheroids were generated by seeding single
cell suspension (5 × 10³ cells/well) with viability above 90% in
Corning® Costar® 96 well round bottom ultra-low attachment
plates and cultured in complete medium under standard
conditions for 2–3 days. For longer incubation time, spheroids
were fed every 4 days by carefully replacing half medium by
fresh complete medium. Spheroids were stained at day 4, 8,
and 14 with propidium iodide (1 µg/mL, Miltenyi Biotec) for
3 h at 37°C and with Hoechst 33342 (ThermoFisher) at 1
mg/mL for 30 min at 37°C for detection of necrotic core and
proliferation zones, respectively. Spheroids were imaged using
an inverted transmitted light/fluorescence microscope (EVOS FL
Auto Imaging system, Life Technologies). Spheroid diameters
were determined using ImageJ software (NIH, Bethesda, MD;
http://imagej.nih.gov/ij and their size was calculated using
the formula: V = 4/3πr³. Spheroid size reproducibility was
determined using the percent of coefficient of variation [CV (%)].
A CV inferior to 15% indicated a homogenous sample.

Immunohistochemistry on Spheroids

Spheroids were fixed for 1 h at room temperature in 4% methanol free-formaldehyde, embedded in 5% agarose before embedding in paraffin for immunostaining analysis. An antigen retrieval step at acidic pH (pH 6) was performed before immunohistochemical staining of spheroid sections (4 µm) for all antibodies except for anti E-cadherin antibody (pH 9). Staining was performed with anti-Ki-67 (1:50, Sigma-Aldrich), anti-E-cadherin (1:250, Abcam) and anti-vimentine (1:400, Abcam) and immunoreactivities were detected using the VECTASTAIN® ABC Kit (Vector Laboratories) according to the manufacturer's protocol and liquid diaminobenzidine substrate chromogen system (Dako; K3468). Counter-staining in Mayer Hematoxilin followed by a bluing step in 0.1% sodium bicarbonate buffer was performed before mounting of the sections.

3D Migration and Invasion Assays

For the migration assays, 4 day-spheroids were transferred into a 96 well flat bottom plate (Clear flat bottom surface Corning® Costar®, Life Sciences) pre-coated with 1% gelatin (Sigma-Aldrich) in DMEM-5% FBS (MDA-MB 231) or RPMI-1% FBS (HCC1806) medium. For the invasion assays, 4-day spheroids were embedded in 50% Matrigel (BD Matrigel™ Basement Membrane Matrix Phenol Red free, BD Biosciences). Once Matrigel solidified, 100 µl of complete culture medium was added on top. Images of the spheroids were captured during 72 h and analyzed using ImageJ software.

2D Migration and Invasion Assays

Two-dimensional migration was investigated using 8 µm FluoroBlok™ (Corning® Fluoroblok™ Cell Culture Inserts, BD biosciences). Two days before the assay, tumor cells were stained with 10 µM carboxyfluorescein diacetate succidimyl ester (CellTrace™ CFSE Cell Proliferation kit, ThermoFisher Scientific) for 20 min at 37°C. One day before, cell cycle synchronization was performed by serum starvation. The upper chambers were seeded with CFSE-labeled tumor cells (10⁵) in RPMI medium with or without bsFab (50 nM). Chemotactic gradient was created by addition of 5% FBS medium in the lower chamber. The fluorescence in the bottom chamber measured at 6 and 24 h on a fluorescent plate reader (Tecan Infinite® M1000—Life Technologies) at 521 nm corresponds to the migrating cells.

Invasion assays were performed as above using 8 µm FluoroBlock™ inserts pre-coated with 1 mg/ml Matrigel.

For each experiment, fluorescence values for the control + 5% FBS were set as 100% migration/invasion. The ratiometric results were expressed relative to this sample.

In vitro NK Cell-Mediated ADCC Assays

Two-dimensional *in vitro* assays with fresh human NK cells were
performed using CellTiter-Glo Luminescent Cell Viability Assay
(Promega) as previously described (22). 3D ADCC assays were
performed by flow cytometry using CFSE (1 µM)-prestained
MDA-MB 231 or HCC1806 spheroids. The size homogeneity
of spheroids was verified by imaging prior cytotoxicity assays.
At day 2, antibodies (5 nM) and purified human NK cells at various E/T ratios were added in the medium. After overnight incubation, washed spheroids were dissociated with TrypLE express (LifeTechnologies) for 5–10 min at 37°C. Cells were immunostained with an APC-conjugated anti-CD45 (1/40, Miltenyi Biotec), then with 1 µM SYTOX® blue (Molecular Probes, LifeTechnologies) for 5–20 min, in the dark. Quadrant statistics was applied on the dot plots. CD45-APC<sup>negative</sup> tumor cells were gated and remaining viable tumor cells were identified as APC<sup>-</sup>/CFSE<sup>+</sup>/SYTOX Blue<sup>-</sup>. Percent specific cytotoxicity was calculated as follows: $[TEA^{CFSE+SYTOX-} - TE^{CFSE+SYTOX-}]/[TE^{CFSE+SYTOX-}]$ with TEA = Target + Effector + Antibody, TE = Target + Effector, and T = Target.

## In vitro PBMC-Mediated ADCC Assays

Human PBMCs were isolated from healthy donors via Ficoll Histopaque® (Sigma-Aldrich) density gradient centrifugation. The NK cell fraction was depleted by incubation of PBMC with MACS® CD56 MicroBeads, human (Miltenyi, #130-050-401) followed by manual separation using MACS LD Columns (Miltenyi) following the manufacturer's instructions. The CD56-depleted fraction was collected and stained with anti-human CD3-PE, anti-human CD16-PE, and anti-human CD56-APC antibodies (Miltenyi) for 30 min at 4°C.

Flow cytometry-based cytotoxicity assays were performed with PBMC and CD56-depleted PBMC. Target cells (HCC1806, SK-BR-3) were stained with 1 µM carboxyfluorescein diacetate succinimidyl ester (CFSE—LifeTechnologies) according to manufacturer's instructions. Following labeling, the cells were washed and analyzed by flow cytometry for viability (>95%). Effector cells were preincubated with antibodies (40 nM) for 20 min at 37°C then co-incubated with CFSE-labeled tumor cells (4 × 10⁴/well) at effector/target (E:T) ratio of 25 in RPMI-GlutaMAX™ medium supplemented with 10% FBS for 3 h. Cells were washed with PBS/BSA 2%, stained with TO-PRO®-3 (1/1000) (LifeTechnologies) and analyzed by flow cytometry on a MACSQuant cytometer. Gating on TO-PRO®-3/CFSE double positive cells indicated dead target cells in percentage (%). Percent specific cytotoxicity was calculated as follows: $[TEA^{CFSE+TO-PRO3+} - TE^{CFSE+TO-PRO3+}]/100 - TE^{CFSE+TO-PRO3+}$] with TEA = Target + Effector + Antibody, TE = Target + Effector.

## NK Cell Activation Assays

Supernatants of 2D and 3D ADCC assays were harvested and frozen at -20°C. Secreted human IFNγ, TNFα, and granzyme B were measured by ELISA using the READY-SET-GO human IFNγ or TNFα kits or the Human Granzyme B platinum ELISA kit as described by the manufacturer (eBioscience).

## 3D NK Cells Recruitment

Purified human NK cells (2 × 10⁶ cells) were labeled with 0.4% PKH26 (MINI26, Sigma Aldrich) during 5 min at 4°C, in the dark and with stirring. At day 2, CFSE stained HCC1806 spheroids were mixed with PKH26-labeled NK cells (12 500 cells) (E:T=2.5:1) and antibodies (50 nM). After 48 h incubation, imaging was performed using a LightSheet Z.1 microscope (Carl Zeiss Microscopy, GmbH, Jena, Germany) along 4 different

angular views, every 90° for 3D reconstruction using the Multiview Reconstruction plugin for Fiji (36) and automated using a jython script. View alignments were performed using the RANSAC algorithm and fluorescent beads as interest-point. The fusions were performed with a mean of the different views. Jython scripts for Fiji were used for measuring NK cell infiltration. For each spheroid, a mask was created using an intensity threshold on the CFSE-labeled tumor image and manuals corrections to remove holes and protuberance to respect the spheroid shape. PKH26-labeled NK cells were detected with the Regional Min and Max 3D (Morpholibj plugin) (49) after a Laplacian of Gaussian filtering (with a size 6 µm, the FeatureJ plugin (https://imagescience.org/meijering/software/featurej/). The local maxima detections were filtered by removing the detection outside the spheroid mask and by an intensity threshold of 1 (on the Laplacian of Gaussian image). The NK cells depths were measured by calculating the Chamfer Distance Map 3D of the spheroid mask with the Morpholibj plugin (26).

## In vivo Tumor Growth Studies

All animal experiments were performed in agreement with the French Guidelines for animal handling and approved by the local ethic committee (C2EA14) for Animal Experimentation (Agreement no. APAFIS#13350-2018012313504256v4). HCC1806 (2 × 10⁵ cells/mice) and MDA MB 231 (1 × 10⁶ cells/mice) in a 1/2 (v/v) Matrigel (Corning Life Sciences, Bedford, MA, USA) suspension were injected into mammary fat pads of 8-week-old female NSG mice. For HCC1806 models, freshly purified human PBMCs (15 × 10⁶ cells/mice) pre-incubated with MesobsFab (5 mg/kg, *n* = 6 mice/group) or control human IgG (5 mg/kg, *n* = 6 mice/group) were injected intravenously (i.v) at days 1 and 7 post-graft. From day 2 to 12, MesobsFab and hu IgG (5 mg/kg) were injected (i.p) daily and every 3 days, respectively. For MDA MB 231 models, mice were randomly divided into treatment groups (*n* = 6 mice/group) when tumors reached an average of 30–40 mm³ (28 days post-graft) and human PBMCs pre-incubated with Mesobsfab or human IgG (5 mg/kg) were injected i.v. During the next 10 days, MesobsFab and hu IgG (5 mg/kg) were injected i.p daily and every 3 days, respectively. A second injection i.v. of PBMCs pre-incubated with antibodies was performed 7 days after the first one. Tumor growth was monitored by digital caliper measurements and by calculating volumes (length × width² × π/6).

## Statistical Analysis

In all graphs data are presented as mean ± SEM. One-tailed or two-tailed unpaired Student's *t*-test (in vitro experiments) and Two-Way ANOVA with Bonferroni post tests (in vivo) were performed using a 95% confidence interval using Prism 5 (GraphPad software). *P*-values < 0.05 were considered significant.

## ETHICS STATEMENT

This study was carried out in accordance with the French guidelines for animal handling and protection. The protocol was
approved by the animal ethics committee C2EA14 (Agreement no. APAFIS#13350-2018012313504256-v4).

## AUTHOR CONTRIBUTIONS

JD and BK: conceptualization. JD, RF-F, and LG: methodology. JD and LG: investigation. EJ, AG, and RC: animal studies. PC and BK: supervision. JD, PC, and BK: writing. DB and BK: funding acquisition.

## FUNDING

This work was supported by institutional grants from INSERM and CNRS and a partnership with GEFLUC. JD was supported by the Assistance Publique des Hôpitaux de Marseille.

## REFERENCES

1. Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. *Cancer J.* (2008) 14:343–51. doi: 10.1097/PPO.0b013e31818d839b

2. Chang K, Pastan I, Willingham MC. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. *Int J Cancer.* (1992) 51:548–54. doi: 10.1002/ijc.2910510408

3. Timmins NE, Nielsen LK. Generation of multicellular tumor spheroids by the hanging-drop method. *Methods Mol Med.* (2007) 140:141–51. doi: 10.1007/978-1-59745-443-8_8

4. Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. *Cancer Sci.* (2008) 99:590–4. doi: 10.1111/j.1349-7006.2007.00715.x

5. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. *Mol Cell Biol.* (2000) 20:2902–6. doi: 10.1128/MCB.20.8.2902-2906.2000

6. Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? *J Clin Oncol.* (2016) 34:4171–9. doi: 10.1200/JCO.2016.68.3672

7. Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. *Anticancer Agents Med Chem.* (2013) 13:276–80. doi: 10.2174/1871520611313020014

8. Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. *Mol Cancer Res.* (2008) 6:186–93. doi: 10.1158/1541-7786.MCR-07-0254

9. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. *Clin Cancer Res.* (2012) 18:2478–89. doi: 10.1158/1078-0432.CCR-11-2614

10. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. *Mol Cancer.* (2006) 5:50. doi: 10.1186/1476-4598-5-50

11. Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. *Sci Rep.* (2013) 3:1870. doi: 10.1038/srep01870

12. Tan K, Kajino K, Momose S, Masaoka A, Sasahara K, Shiomi K, et al. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. *Hum Pathol.* (2010) 41:1330–8. doi: 10.1016/j.humpath.2010.03.002

13. Prieve MG, Moon RT. Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. *BMC Dev Biol.* (2003) 3:2. doi: 10.1186/1471-213X-3-2

## ACKNOWLEDGMENTS

The authors thank MN Lavaut for her assistance with immunochemical analysis of spheroids, J. Rambeloson for performing flow cytometry-based cytotoxicity assays and E. Termine for her helpful technical assistance. We acknowledge the IBDM imaging facility, member of the France-BioImaging infrastructure supported by the French National Research Agency (ANR-10-INBS-04-01, Investments for the future).

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.01593/full#supplementary-material

14. Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H. Novel antibody therapeutics targeting mesothelin in solid tumors. *Clin Cancer Drugs.* (2016) 3:76–86. doi: 10.2174/2212697X03666160218215744

15. Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. *JCI Insight.* (2018) 3:99573. doi: 10.1172/jci.insight.99573

16. Baldo P, Cecco S. Amatuximab and novel agents targeting mesothelin for solid tumors. *Onco Targets Ther.* (2017) 10:5337–53. doi: 10.2147/OTT.S145105

17. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. *Breast Cancer Res Treat.* (2012) 133:799–804. doi: 10.1007/s10549-012-2018-4

18. Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. *PLoS ONE.* (2014) 9:e114900. doi: 10.1371/journal.pone.0114900

19. Li YR, Xian RR, Ziober A. Conejo-Garcia J, Perales-Puchalt A, June CH, et al. Mesothelin expression is associated with poor outcomes in breast cancer. *Breast Cancer Res Treat.* (2014) 147:675–84. doi: 10.1007/s10549-014-3077-5

20. Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, Varol U, Yildiz I, Alacacioglu A, et al. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. *Biomed Pharmacother.* (2015) 70:190–5. doi: 10.1016/j.biopha.2015.01.019

21. Rozan C, Cornillon A, Petiard C, Chartier M, Behar G, Boix C, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting FcgammaRIII induce potent antitumor activity without recruiting regulatory T cells. *Mol Cancer Ther.* (2013) 12:1481–91. doi: 10.1158/1535-7163.MCT-12-1012

22. Turini M, Chames P, Bruhns P, Baty D, Kerfelec B. A FcgammaRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. *Oncotarget.* (2014) 5:5304–19. doi: 10.18632/oncotarget.2093

23. Prantner AM, Turini M, Kerfelec B, Joshi S, Baty D, Chames P, et al. Anti-mesothelin nanobodies for both conventional and nanoparticle-based biomedical applications. *J Biomed Nanotechnol.* (2015) 11:1201–12. doi: 10.1166/jbn.2015.2063

24. Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. *Protein Eng Des Sel.* (2008) 21:1–10. doi: 10.1093/protein/gzm064

25. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. *Nat Protoc.* (2009) 4:309–24. doi: 10.1038/nprot.2008.226

26. Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: the next frontier in precision oncology. *Oncotarget.* (2017) 8:106167–8. doi: 10.18632/oncotarget.22580
27. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. *PLoS ONE*. (2012) 7:e33214. doi: 10.1371/journal.pone.0033214

28. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. *Mol Cancer Ther*. (2012) 11:517–25. doi: 10.1158/1535-7163.MCT-11-0454

29. Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma *in situ* of the breast. *Br J Cancer*. (2008) 98:137–42. doi: 10.1038/sj.bjc.6604112

30. Li H, Qiu Z, Li F, Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. *Oncol Lett*. (2017) 14:5865–70. doi: 10.3892/ol.2017.6924

31. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. *Oncotarget*. (2014) 5:2736–49. doi: 10.18632/oncotarget.1932

32. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. *Cancer Immunol Immunother*. (2010) 59:1675–84. doi: 10.1007/s00262-010-0894-1

33. Kunz-Schughart LA, Kreutz M, Knuechel R. Multicellular spheroids: a three-dimensional *in vitro* culture system to study tumour biology. *Int J Exp Pathol*. (1998) 79:1–23. doi: 10.1046/j.1365-2613.1998.00051.x

34. Bruns T, Schickinger S, Wittig R, Schneckenburger H. Preparation strategy and illumination of three-dimensional cell cultures in light sheet-based fluorescence microscopy. *J Biomed Opt*. (2012) 17:101518. doi: 10.1117/1.JBO.17.10.101518

35. Pampaloni F, Ansari N, Stelzer EH. High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopy. *Cell Tissue Res*. (2013) 352:161–77. doi: 10.1007/s00441-013-1589-7

36. Preibisch S, Amat F, Stamataki E, Sarov M, Singer RH, Myers E, et al. Efficient Bayesian-based multiview deconvolution. *Nat Methods*. (2014) 11:645–8. doi: 10.1038/nmeth.2929

37. Deguine J, Bousou P. Dynamics of NK cell interactions *in vivo*. *Immunol Rev*. (2013) 251:154–9. doi: 10.1111/imr.12015

38. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. *PLoS ONE*. (2007) 2:e326. doi: 10.1371/journal.pone.0000326

39. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. *Proc Natl Acad Sci USA*. (2011) 108:728–32. doi: 10.1073/pnas.1012356108

40. Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, et al. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. *J Immunol*. (2014) 193:4261–72. doi: 10.4049/jimmunol.1400872

41. Alspach E, Lussier DM, Schreiber RD. Interferon gamma and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. *Cold Spring Harb Perspect Biol*. (2018) 11:a028480. doi: 10.1101/cshperspect.a028480

42. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. *Blood*. (2010) 115:2167–76. doi: 10.1182/blood-2009-08-238469

43. Zervos E, Agle S, Freistaedter AG, Jones GJ, Roper RL. Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer. *J Exp Clin Cancer Res*. (2016) 35:39. doi: 10.1186/s13046-016-0314-2

44. Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, et al. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. *Sci Rep*. (2016) 6:34310. doi: 10.1038/srep34310

45. Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, Introna M. Human neutrophils express low levels of FcgammaRIIIA, which plays a role in PMN activation. *Blood*. (2019) 133:1395–405. doi: 10.1182/blood-2018-07-864538

46. Pahl JHW, Koch J, Gotz JJ, Arnold A, Reusch U, Gantke T, et al. CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. *Cancer Immunol Res*. (2018) 6:517–27. doi: 10.1158/2326-6066.CIR-17-0550

47. Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. *Expert Opin Biol Ther*. (2015) 15:1093–9. doi: 10.1517/14712598.2015.1041373

48. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. Antiserum albumin domain antibodies for extending the half-lives of short lived drugs. *Protein Eng Des Sel*. (2008) 21:283–8. doi: 10.1093/protein/gzm067

49. Legland D, Arganda-Carreras I, Andrey P. MorphoLib: integrated library and plugins for mathematical morphology with ImageJ. *Bioinformatics*. (2016) 32:3532–4. doi: 10.1093/bioinformatics/btw413

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Del Bano, Florès-Florès, Josselin, Goubard, Ganier, Castellano, Chames, Baty and Kerfelec. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.